Tirzepatide (TZP) is a novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist in development for T2D. In a continuous glucose monitoring (CGM) sub-study of SURPASS-3 (NCT03882970) , participants with T2D on metformin with or without SGLT-2 inhibitors spent up to 91% of time in range (71-180 mg/dL) for TZP (5, 10, 15 mg) vs. 75% for insulin degludec (IDeg) (p<0.001) and within-day coefficient of variation was 16% vs. 24% for TZP vs. IDeg (p<0.001) . Reported here are additional pre-specified glycemic variability (GV) measures at 52 weeks for the sub-study (N=243; mean age of participants, 57 years; T2D duration, 8.8 years; baseline HbA1c, 8.14%) . The between-day GV measured as the mean of daily differences was significantly less for TZP vs. IDeg (TZP 5-15 mg; p<0.001) . The frequency and severity of hypoglycemic events measured by the low blood glucose (BG) index were significantly lower at all doses of TZP vs. IDeg (mg: p<0.05; 5, 15 mg: p<0.001) , as were hyperglycemic events measured by the high BG index compared to IDeg (5 mg: p<0.05; 10, 15 mg: p<0.001) . The BG risk index was significantly less at all doses of TZP (5 mg: p<0.05; 10, 15 mg: p<0.001) (Table) . TZP showed clinically meaningful and significant reductions in the risk of hyperglycemia and hypoglycemia in comparison to IDeg in people with T2D.
R.M.Bergenstal: Advisory Panel; Hygieia, Medtronic, Roche Diabetes Care, Zealand Pharma A/S, Consultant; Abbott Diabetes, Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur SA, Dexcom, Inc., Eli Lilly and Company, Novo Nordisk, Onduo LLC, Sanofi, United HealthCare Services, Inc., Research Support; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk, Sanofi. A.Bartee: None. M.Zeytinoglu: Employee; Eli Lilly and Company. R.Bray: Employee; Eli Lilly and Company. S.Allen: None. K.Brown: Employee; Eli Lilly and Company.